BeOne Medicines
ONC
#652
Rank
HK$278.15 B
Marketcap
HK$2,514
Share price
-2.56%
Change (1 day)
60.18%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeOne Medicines (ONC) - P/B ratio

P/B ratio as of December 2025 : 8.57

According to BeOne Medicines's latest financial reports the company has a price-to-book ratio of 7.11567.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

BeOne Medicines - P/B ratio (from 2016 to 2025)

P/B ratio by year

Year P/B ratio Change
2025-12-31N/A-100%
2024-12-316.1510.28%
2023-12-315.57-3.95%
2022-12-315.8028.03%
2021-12-314.53-25.92%
2020-12-316.12-41.43%
2019-12-3110.4119.14%
2018-12-314.77-26.73%
2017-12-316.5090.55%
2016-12-313.41
2015-12-31N/A
2014-12-31N/A

P/B ratio for similar companies or competitors

Company P/B ratio P/B ratio differencediff. Country
Onconova Therapeutics
ONTX
3.48-59.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
0.8208-90.42%๐Ÿ‡บ๐Ÿ‡ธ USA